A medical device's intended purpose - what is the point?

Dr Simon Cumiskey
Considering a medical device's intended purpose

A clear idea of your medical device’s intended purpose is crucial in meeting the EU MDR regulatory requirements. Getting it right early in the development process is important, as it provides inputs to:

  1. Objectives of the Clinical Evaluation,
  2. Defining the SOTA,
  3. Design of clinical investigations,
  4. Equivalence claims,
  5. Evidence for conformity to relevant GSPRs.

A clinical evaluation should, according to its definition in Article 2(44) of the EU MDR, “verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer.”

But what is the intended purpose, and how does it interact with indications for use, claims, and intended clinical benefits? For each term, we will consider a fictional hip implant device.

Intended purpose

‘Intended purpose’ should describe what the device is used for and the effect of the device. Article 2(12) of the EU MDR defines ‘intended purpose’ as “the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation.”

All medical devices will have an intended purpose. In the case of a hip implant, the intended purpose could be for the replacement of native hip joints in adult patients with moderate to severe hip osteoarthritis.

Indication for use

‘Indication for use’ should describe the clinical condition that the device targets. MDCG 2020-6 defines the indication for use as “the clinical condition that is to be diagnosed, prevented, monitored, treated, alleviated, compensated for, replaced, modified or controlled by the medical device.”

Some devices, therefore, may not have an indication for use. An example would be a medical device intended to sterilise equipment. In the case of a hip implant, the indication for use could be hip osteoarthritis with an Oxford Hip Score less than 29.

Clinical benefit

‘Clinical benefit’ should describe the benefit to the patient from using the device in a quantifiable manner. Article 2(53) of the EU MDR defines clinical benefit as “the positive impact of a device on the health of an individual, expressed in terms of a meaningful, measurable, patient-relevant clinical outcome(s), including outcome(s) related to diagnosis, or a positive impact on patient management or public health.”

All devices will have a clinical benefit, but these can be either direct or indirect. In the case of a hip implant, the intended clinical benefit could be the reduction in pain VAS score by 25%. An example of a medical device with an indirect clinical benefit would be the scalpel used during the operation; a scalpel will not reduce pain in patients with osteoarthritis, but will facilitate insertion of the hip replacement and therefore lead to an improvement in pain VAS score.

Claims

‘Claims’ are not defined in the EU MDR, but Article 7 prohibits any information supplied by the manufacturer that may mislead the user with regard to the intended purpose, safety, or performance. Claims, therefore, can be derived from any manufacturer documents and should be supported by clinical evidence in the clinical evaluation.

Claims will encompass all of the intended use, indications for use, clinical benefits, as well as other terms not discussed in this article such as intended user, use environment, etc.

Summary

To briefly summarise each of the points above:

Intended purpose Is the use and effect of the device.
Indications for use Is the clinical condition that the device targets.
Clinical benefit Is the measurable impact on the patient.
Claims Derived from the above, plus any other claims made in marketing materials, IFU, etc.

For further information on how we can help you meet your MDR requirements please contact us for a free and confidential discussion.

Alternatively, for any general regulatory questions you need a quick answer to, have you tried our AI-powered MDR & MDCG chatbot? — it’s free and will answer your queries around the clock.

Related articles

  1. US and EU flags on poles alongside each other.

    Clinical Evidence under EU MDR: Leveraging FDA Clinical Data to Streamline EU MDR Compliance

    FDA approval alone is not sufficient for European market access - a theme we explore futher in this article and the accompanying webinar.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  2. An AI-generated image of 3 people in an office in front of a whiteboard with the words 'Medical Device Market Entry Strategy' written above a world map.

    EU MDR & NHS DTAC Cybersecurity Requirements for UK Market Entry

    This guest article from our partner Cyber Alchemy shows you how to build cybersecurity evidence for the EU MDR and NHS DTAC.

    Luke Hill Luke Hill Co-Founder of Cyber Alchemy
  3. An illustration showing a GPS-driven navigation route superimposed upon someone using a laptop.

    Where to Launch First? A MedTech Founder's Regulatory Roadmap to the EU, UK and US

    Cyber Alchemy × Mantra Systems — Episode 1: All three markets operate under different regulatory systems and place different demands on manufacturers.

    Ronghe Xu Ronghe Xu Regulatory Medical Writer & Strategic BD Lead China
  4. A woman uses an inhaler.

    Navigating EU MDR Article 117: A Practical Guide to Drug-Device Combination Product Submissions

    Implementation of the EU MDR 2017/745 has brought significant changes.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  5. Collage art showing a pair of binoculars, an analogy for surveillance.

    How EU MDR Post Market Surveillance differs from FDA post-market expectations

    We compare manufacturer-specific post-market obligations across both regulatory systems.

    Dr Gayle Buchel Dr Gayle Buchel Chief Medical Writer
  6. An arrow arcs from the US over to Europe.

    How EU device classification differs from the US - Are you Prepared?

    Did you know an FDA Class II medical device could be immediately considered as a high-risk Class III device under European Union regulations?

    Gabriela Cardoso Gabriela Cardoso Regulatory Medical Writer
  7. A magnifying glass inspecting a number of wooden cubes with question marks upon them laid upon a blue table. The wooden cube under the magnifying glass has a lightbulb painted on it.

    Fixing the MDR and IVDR? The Commission’s Proposed Amendments and What They Mean for Manufacturers

    Exploring the key elements of this proposal.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  8. An illustration showing a business woman pole-vaulting across a ravine.

    Eliminating the Top 5 Notified Body Gaps in Clinical Evaluation Through Pre-Submission Review

    From insufficient clinical evidence to Post-Market issues - we guide you past common NB deficiencies.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  9. Two arms point at a sign and hold a question mark, in an abstract pop-art style.

    Regulatory Reset? The EU’s Proposed Changes to MDR and IVDR Explained

    Changes published in December 2025 aim to streamline EU medical device and in vitro diagnostics. We explain who is impacted and how.

    Dr Gayle Buchel Dr Gayle Buchel Chief Medical Writer
  10. A pair of glasses rests on an eye test chart.

    Did You Know Your Glasses Were a Medical Device? A Regulatory Guide for Manufacturers

    The importance of correct classification and our recommended path to avoid common ophthalmic device 'gotchas'.

    Gabriela Cardoso Gabriela Cardoso Regulatory Medical Writer
  11. A man sitting whilst a nurse prepares his arm for an injection.

    Why Clinical Trial Design Should Begin at the Earliest Stages of Medical Device Development

    In this guest post from our partners at Franklyn Health, they explore the benefits of a well-planned approach.

    Rob Bedford Rob Bedford Head of Clinical Operations at Franklyn Health

More articles

Need help producing compliant CEPs & CERs? We are offering FREE CEPs to 5 qualifying applicants per week

Get your free CEP